MX2017017049A - Anticuerpos anti antigeno de celulas nk y linfocitos t y b (ntb-a) y composiciones y metodos relacionados. - Google Patents

Anticuerpos anti antigeno de celulas nk y linfocitos t y b (ntb-a) y composiciones y metodos relacionados.

Info

Publication number
MX2017017049A
MX2017017049A MX2017017049A MX2017017049A MX2017017049A MX 2017017049 A MX2017017049 A MX 2017017049A MX 2017017049 A MX2017017049 A MX 2017017049A MX 2017017049 A MX2017017049 A MX 2017017049A MX 2017017049 A MX2017017049 A MX 2017017049A
Authority
MX
Mexico
Prior art keywords
ntb
antibodies
methods
related compositions
disclosed
Prior art date
Application number
MX2017017049A
Other languages
English (en)
Inventor
Sussman Django
Lewis Timothy
WESTENDORF Lori
Leung Law Che-
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2017017049A publication Critical patent/MX2017017049A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a anticuerpos, que incluyen conjugados de fármaco de anticuerpo, que se unen específicamente a NTB-A. También se describen métodos para usar los anticuerpos anti-NTB-A para detectar o modular la actividad de (por ejemplo, inhibir la proliferación de) una célula que expresa NTB-A, así como también para diagnósticos o tratamiento de enfermedades o trastornos (por ejemplo, cáncer) asociados con células que expresan NTB-A, tales como mieloma múltiple, linfoma no Hodgkin y leucemia mieloide aguda.
MX2017017049A 2015-06-30 2016-06-30 Anticuerpos anti antigeno de celulas nk y linfocitos t y b (ntb-a) y composiciones y metodos relacionados. MX2017017049A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186596P 2015-06-30 2015-06-30
US201662321849P 2016-04-13 2016-04-13
PCT/US2016/040307 WO2017004330A1 (en) 2015-06-30 2016-06-30 Anti-ntb-a antibodies and related compositions and methods

Publications (1)

Publication Number Publication Date
MX2017017049A true MX2017017049A (es) 2018-03-06

Family

ID=57609137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017017049A MX2017017049A (es) 2015-06-30 2016-06-30 Anticuerpos anti antigeno de celulas nk y linfocitos t y b (ntb-a) y composiciones y metodos relacionados.

Country Status (22)

Country Link
US (2) US11351269B2 (es)
EP (2) EP4302784A3 (es)
JP (2) JP6879947B2 (es)
KR (1) KR20180021705A (es)
CN (2) CN116063502A (es)
AU (2) AU2016287647A1 (es)
BR (1) BR112017027498A2 (es)
CA (1) CA2986796A1 (es)
DK (1) DK3316909T3 (es)
EA (1) EA201890158A1 (es)
ES (1) ES2955961T3 (es)
FI (1) FI3316909T3 (es)
HK (1) HK1253306A1 (es)
HU (1) HUE063320T2 (es)
IL (2) IL303690A (es)
MX (1) MX2017017049A (es)
PL (1) PL3316909T3 (es)
PT (1) PT3316909T (es)
SG (1) SG10202005460RA (es)
SI (1) SI3316909T1 (es)
WO (1) WO2017004330A1 (es)
ZA (1) ZA201707869B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100740A1 (en) * 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
IL303690A (en) 2015-06-30 2023-08-01 Seagen Inc Anti–NTB–A antibodies and related preparations and methods
CN111164208B (zh) 2017-09-29 2023-08-04 第一三共株式会社 抗体－吡咯并苯并二氮杂卓衍生物偶联物
TW202031298A (zh) 2018-11-14 2020-09-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體－吡咯并苯二氮呯衍生物結合物
WO2020196474A1 (ja) 2019-03-25 2020-10-01 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
CA3191804A1 (en) 2019-03-25 2020-10-01 Daiichi Sankyo Company, Limited Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
TW202102226A (zh) 2019-03-27 2021-01-16 日商第一三共股份有限公司 抗體-吡咯并苯二氮呯衍生物結合物及parp抑制劑之組合
US20220372137A1 (en) 2019-07-03 2022-11-24 Oxford Biotherapeutics Ltd Antibodies and methods of use
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
CN114929284A (zh) 2019-10-04 2022-08-19 西根公司 喜树碱肽缀合物
EP4069374A1 (en) * 2019-12-06 2022-10-12 Thoas Fioretos Novel agents and uses thereof
IL297167A (en) 2020-04-10 2022-12-01 Seagen Inc Charging variant connectors
JPWO2022050300A1 (es) 2020-09-02 2022-03-10
KR20230146521A (ko) 2021-01-13 2023-10-19 메모리얼 슬로안 케터링 캔서 센터 항체-피롤로벤조디아제핀 유도체 접합체
KR20230171980A (ko) 2021-04-20 2023-12-21 씨젠 인크. 항체 의존성 세포 독성의 조절
CA3221398A1 (en) 2021-05-28 2022-12-01 Seagen Inc. Anthracycline antibody conjugates
WO2023178289A2 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
JP2000503639A (ja) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー 分枝ヒドラゾンのリンカー類
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
CN100405399C (zh) 1999-02-05 2008-07-23 三星电子株式会社 图像纹理恢复方法及其装置
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
DE10355904A1 (de) * 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
EA016357B1 (ru) 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Антитела, направленные против бета-амилоидного пептида, и способы их применения
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
CA2659820A1 (en) * 2006-08-04 2008-02-14 Novartis Ag Ephb3-specific antibody and uses thereof
US7847067B2 (en) * 2006-08-28 2010-12-07 ARCA Biopharma Antibodies to NTB-A
US8455622B2 (en) 2006-12-01 2013-06-04 Seattle Genetics, Inc. Variant target binding agents and uses thereof
HUE031533T2 (hu) 2007-10-19 2017-07-28 Seattle Genetics Inc CD19-kötõszerek valamint alkalmazásuk
AU2011239522B2 (en) 2010-04-15 2014-10-23 Medimmune Limited Targeted pyrrolobenzodiazapine conjugates
US10472679B2 (en) 2012-05-15 2019-11-12 Cornell University Non-invasive method of diagnosing renal fibrosis
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2014100740A1 (en) * 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
KR102034478B1 (ko) * 2013-03-14 2019-10-21 시오노기 앤드 컴파니, 리미티드 혈관내피 리파제의 효소 활성을 저해하는 모노클로널 항체
CN105916882A (zh) * 2013-12-16 2016-08-31 得克萨斯技术大学联合体 作为用于靶向癌症治疗的细胞毒性药物递送系统的抗-ron单克隆抗体
TWI734410B (zh) * 2014-09-11 2021-07-21 日商塩野義製藥股份有限公司 阻礙血管內皮脂酶之酵素活性的人類化單株抗體
IL303690A (en) 2015-06-30 2023-08-01 Seagen Inc Anti–NTB–A antibodies and related preparations and methods
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors

Also Published As

Publication number Publication date
WO2017004330A1 (en) 2017-01-05
PT3316909T (pt) 2023-11-22
EP3316909A1 (en) 2018-05-09
IL256295A (en) 2018-02-28
DK3316909T3 (da) 2023-11-13
HUE063320T2 (hu) 2024-01-28
CN107735105B (zh) 2022-09-16
CN116063502A (zh) 2023-05-05
BR112017027498A2 (pt) 2018-09-11
KR20180021705A (ko) 2018-03-05
JP6879947B2 (ja) 2021-06-02
AU2016287647A1 (en) 2017-12-07
EP4302784A2 (en) 2024-01-10
SI3316909T1 (sl) 2023-10-30
US11351269B2 (en) 2022-06-07
EP4302784A3 (en) 2024-03-13
US20180169257A1 (en) 2018-06-21
CA2986796A1 (en) 2017-01-05
ZA201707869B (en) 2023-10-25
JP2021087427A (ja) 2021-06-10
JP2018520671A (ja) 2018-08-02
HK1253306A1 (zh) 2019-06-14
ES2955961T3 (es) 2023-12-11
EA201890158A1 (ru) 2018-06-29
EP3316909A4 (en) 2019-01-09
US20230218776A1 (en) 2023-07-13
CN107735105A (zh) 2018-02-23
EP3316909B1 (en) 2023-08-30
PL3316909T3 (pl) 2023-11-20
SG10202005460RA (en) 2020-07-29
AU2022209203A1 (en) 2022-09-15
IL256295B1 (en) 2023-07-01
FI3316909T3 (fi) 2023-09-07
JP7194762B2 (ja) 2022-12-22
IL256295B2 (en) 2023-11-01
IL303690A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
ZA201707869B (en) Anti-ntb-a antibodies and related compositions and methods
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
MX2022008184A (es) Anticuerpos anti pd-1 y anti-lag3 para usarse en el tratamiento de cancer.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
AU2017228470A8 (en) Combination therapy with anti-CD73 antibodies
PH12016501680A1 (en) Anti-egfrviii antibodies and uses thereof
PH12017501040A1 (en) Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
EP4219559A3 (en) Antibodies for lilrb2
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
EA201691361A1 (ru) Антитела к lag-3 для лечения гематологических злокачественных опухолей
MX2019008065A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
MX2018002166A (es) Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
PH12016501366A1 (en) Novel anti-baff antibodies
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
NZ626242A (en) Anti-asic1 antibodies and uses thereof
MX2020005640A (es) Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.
MY175418A (en) Compositions comprising anti-cd38 antibodies and carfilzomib
AU2018285562A1 (en) Dosage regimes for the administration of an anti-CD19 ADC
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
MX2020009864A (es) Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1.
MX2020009863A (es) Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-l1.
EA202090453A3 (ru) Антитела к cd40